Supplementary Table S1. Demographic characteristics D u r a ti o n f r o m
d i a g n o s Prior Primary Case i Recurrent Gender Age Diagnosis Prior surgery Prior chemotherapy radiation metastatic number s disease therapy disease t o c e ll t h e r a p y , m o n t h s 8 C1-01 M 64 Diffuse large B cell lymphoma no yes yes NA yes 1 2 C1-02 M 60 Renal cell carcinoma 0 yes yes no yes no 7 5 C1-03 M 62 Thymic carcinoma no yes yes yes no 5 2 C2-01 F 62 Ovarian cancer no yes no yes no 6 1 C2-02 M 61 Maxillary cancer 3 yes yes yes yes yes 7 5 C2-03 M 51 Rectosigmoid colon cancer yes yes yes no yes 1 9 C3-01 F 69 Adenoid cystic carcinoma yes yes yes no yes 3 4 C3-02 M 63 Transitional cell carcinoma yes yes no no yes 4 2 C3-03 M 54 Tongue cancer yes yes yes no yes 6 C4-01 M 50 Extranodal NK/T-cell lymphoma, nasal type 9 no yes no NA yes 5 C4-02 M 54 Nasopharyngeal cancer no yes yes yes no 5 1 C4-03 M 62 Non-small cell lung cancer no yes no yes no 5 4 C5-01 M 66 Renal cell carcinoma yes yes no no yes 1 5 C5-02 M 68 Adenoid cystic carcinoma yes yes no no yes 4 1 C5-03 M 74 Esophageal cancer, Stomach cancera no yes yes yes no 2 1 C5-04 F 50 Ovarian cancer 3 yes yes no no yes 9 3 C6-01 M 78 Non-small cell lung cancer yes yes no no yes 5 C6-02 F 48 Adenoid cystic carcinoma 7 yes yes yes no yes 3 C6-03 M 64 Papillary thyroid carcinoma yes no yes no yes 1 1 C6-04 M 55 Non-small cell lung cancer no yes yes yes no 2 Abbreviation: NA, not assessable. aDouble primary cancer. Supplementary Table S2. Post-transfusion kinetics of donor NK cells in recipient peripheral blood
Persistence of donor NK cells by nested PCR Recipient 1st injection 2nd injection 3rd injection
C1-01 1 day ─ ─
C1-02 1 day ─ ─
C1-03 ND ─ ─
C2-01 4 days ─ ─
C2-02 1 hour ─ ─
C2-03 1 hour ─ ─
C5-01 3 days 2 days 1 day
C5-03 2 hours 2 hours 2 hours
C5-04 2 days 1 day 4 hours
C6-02 3 days 1 day 4 hours
C6-03 NA NA NA
C6-04 3 days 2 hours 2 hours Abbreviations: ND, not detected; NA, not applicable for this assay due to the same HLA-DRB1 allele between donor and recipient.